ClinicalTrials.gg
WithdrawnNCT02878681TIDE DMEUpdated Apr 28, 2017

24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.

A Phase 4 interventional study of Ranibizumab and Aflibercept in Visual Impairment Due to Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
84th of 91
0 · median 50
Started
2016
with 3 others
Phase 4
26 of 91
none open now
Registered
77th of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 84th largest by enrollment, is one of 4 that started in 2016, is one of 26 in phase 4, and was the 77th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF levels in DME patients in a detailed time course.

Read the detailed description

The purpose of the study is to compare the effect of monthly intravitreal injections of 0.5 mg ranibizumab and 2.0 mg aflibercept on systemic VEGF levels in patients with visual impairment due to DME over a 24 week period. In addition, the study will also assess the effect on systemic VEGF-A levels when patients are switched from aflibercept to ranibizumab.

03

Conditions studied

  • Visual Impairment Due to Diabetic Macular Edema

Keywords

  • Diabetic Macular Edema.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 or Type 2 diabetes mellitus
  • Visual impairment due to DME
  • BCVA of 78 to 24 (20/32-20/320) ETDRS letters

Exclusion criteria

Exclusion Criteria:

  • Stroke or myocardial infarction less than 3 months prior to screening.
  • Presence of uncontrolled systolic blood pressure or diastolic blood pressure
  • Renal failure requiring dialysis or renal transplant or renal insufficiency
  • Untreated diabetes mellitus
  • Use of any systemic anti-VEGF drugs within 6 months prior to screening.
  • Use of systemic or inhaled for at least 30 consecutive days within 3 months prior to screening.
  • Women who are pregnant or breast feeding or who are menstruating and capable of becoming pregnant* and not practicing a medically approved method of

For either eye:

  • Any active periocular or ocular infection or inflammation
  • Uncontrolled glaucoma
  • Neovascularization of the iris or neovascular glaucoma
  • History of treatment with any anti-angiogenic drugs

For study eye:

  • Atrophy or fibrosis involving the center of the fovea at the time of screening or baseline.
  • Cataract (if causing significant visual impairment), planned cataract surgery during the study period, vitrectomy, aphakia, glaucoma surgery, severe vitreous hemorrhage, rhegm
  • Irreversible structural damage within 0.5 disc diameter of the center of the macula
  • Panretinal laser photocoagulation within 6 months prior to randomization.
  • Focal/grid laser photocoagulation within 3 months prior to randomization.
  • Any intraocular procedure (including cataract surgery, Yttrium-Aluminum-Garnet capsulotomy) within 3 months prior to baseline or anticipated within the next 6 months following
  • Topical ocular corticosteroids administered for at least 30 consecutive days within 3 months prior to screening.
  • Application of intravitreal corticosteroids in vitreous within 6 months prior to screening. Prior application of fluocinolonacetonid releasing implant in vitreous within 36 months prior to screening.

For fellow eye

  • Retinal or choroidal neovascularization or macula edema of any cause Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1

    Monthly intravitreal injections of 0.5 mg ranibizumab for six months

    Drug: Ranibizumab

  • Experimental
    Group 2

    Monthly intravitreal injections of 2 mg aflibercept for the initial three months followed by monthly intravitreal injections of 0.5 mg ranibizumab for the next three months.

    Drug: Ranibizumab · Drug: Aflibercept

  • Experimental
    Group 3

    Monthly injections of 2 mg aflibercept for six months

    Drug: Aflibercept

Interventions

  • 0.5 mg intravitreal injections

    Also known as: Lucentis

  • 2 mg intravitreal injections

    Also known as: Eylea

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) of VEGF-A levels from baseline to week 24

    Systemic VEGF-A levels following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept (Area under the curve) expressed in pg/ml\*days. The AUC will be standardized (=divided) by the individual follow-up time and will be calculated by the trapezoidal rule..

    Time frame: baseline to week 24

Secondary outcomes

  1. Mean Systemic VEGF-A levels in serum for patients in treatment group 1 and treatment group 2 within specific time points

    To compare systemic VEGF-A levels (pg/ml) in patients switching from monthly 2 mg aflibercept injections for first three months to monthly 0.5 mg ranibizumab (treatment group 2) for the next three months compared to patients treated with monthly 0.5 mg ranibizumab (treatment group 1) for six months at specific time points from week 12 to week 24. The comparison will be performed at specific time points between week 12 and week 24, based on the blood samples collected for visits 10 to 16.

    Time frame: Day 7, Day 15, Week 4, week 8, week 12, week 14, week 16, week 18, week 20, week 24

  2. Mean Systemic VEGF-A levels in serum for patients in treatment group 1 and treatment group 3 within specific time points

    To compare systemic VEGF-A levels (pg/ml) in patients switching from monthly 2 mg aflibercept injections for first three months to monthly 0.5 mg ranibizumab (treatment group 2) for the next three months compared to patients treated with monthly 2 mg aflibercept (treatment group 3) for six months at specific time points from week 12 to week 24. The comparison will be performed at specific time points between week 12 and week 24, based on the blood samples collected for visits 10 to 16.

    Time frame: Day 7, Day 15, Week 4, week 8, week 12, week 14, week 16, week 18, week 20, week 24

  3. Proportion of patients reporting ocular and/or systemic adverse events in all the three treatment groups.

    To evaluate ocular and systemic safety in all the three treatment groups. Only treatment-emergent AEs will be summarized. AEs will be summarized by presenting for each treatment group the number and percentage of patients having any AE, having an eye-related AEs, having an AE in each primary system organ class and having each individual AEs based on the preferred term. All other information collected (e.g., severity or relationship to study treatment) will be tabulated and listed as appropriate. Summary tables will also be presented for the subset of AEs suspected to be treatment related.

    Time frame: From Baseline to Week 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2016; primary completion for Sep 2017, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2016
First posted
Aug 25, 2016
StartEst.
Sep 2016
Primary completionEst.
Sep 2017
CompletionEst.
Sep 2017
Last update
Apr 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02878681
Responsible party
Sponsor
First posted
Aug 25, 2016
Start date
Sep 2016 (estimated)
Primary completion
Sep 2017 (estimated)
Completion
Sep 2017 (estimated)
Last update
Apr 28, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ranibizumab · Aflibercept

Start the discussion